{"id":395582,"date":"2020-12-08T10:20:29","date_gmt":"2020-12-08T15:20:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=395582"},"modified":"2020-12-08T10:20:29","modified_gmt":"2020-12-08T15:20:29","slug":"anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/","title":{"rendered":"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BERNARDSVILLE, N.J., Dec.  08, 2020  (GLOBE NEWSWIRE) &#8212; Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced the company will be both presenting and participating in multiple expert sessions during the 3<sup>rd<\/sup> Annual RNA-Targeted Drug Discovery Conference, between Dec. 8-10, 2020.<\/p>\n<p align=\"left\">During the virtual meeting, Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will be giving a company presentation during the meeting and will also serve on an expert panel. Concurrently, Iris Alroy, Ph.D., Vice President of Research and Development at the company, will serve on an expert Q&amp;A panel.<\/p>\n<p align=\"left\">Details regarding each session are as follows:<\/p>\n<p align=\"left\">\n        <strong>Ev<\/strong><br \/>\n        <strong>ent Title<\/strong><br \/>\n        <strong>:<\/strong> Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators<br \/><strong>Presenter: <\/strong>Yochi Slonim<br \/><strong>Date: <\/strong>Wednesday, Dec. 9, 2020<br \/><strong>Time:<\/strong> 9:40 a.m. ET<\/p>\n<p align=\"left\">\n        <strong>Ev<\/strong><br \/>\n        <strong>ent Title<\/strong><br \/>\n        <strong>:<\/strong> Live Panel Q&amp;A \u2013 Ask the Speakers Your Burning Questions<br \/><strong>Presenter: <\/strong>Dr. Iris Alroy<br \/><strong>Date: <\/strong>Wednesday, Dec. 9, 2020<br \/><strong>Time:<\/strong> 10:00 a.m. ET<\/p>\n<p align=\"left\">\n        <strong>Ev<\/strong><br \/>\n        <strong>ent Title<\/strong><br \/>\n        <strong>:<\/strong> From Theory to Reality: How to Target RNA Biology With Small Molecule Approaches<br \/><strong>Presenter: <\/strong>Yochi Slonim<br \/><strong>Date: <\/strong>Wednesday, Dec. 9, 2020<br \/><strong>Time:<\/strong> 1:45 p.m. ET<\/p>\n<p align=\"left\">Historically, the development of highly selective, small molecules targeting RNA biology has often been considered an insurmountable challenge. During the RNA-Targeted Drug Discovery Summit, experts will have an opportunity to promote recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA, which may ultimately lead to the development of more highly selective drugs for a variety of diseases. <\/p>\n<p align=\"left\">\n        <strong>About <\/strong><br \/>\n        <strong>Anima Biotech<\/strong>\n      <\/p>\n<p align=\"left\">Anima Biotech is pioneering Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against undruggable proteins. With our proprietary technology that emits light pulses from ribosomes, we identify drug candidates that selectively decrease or increase the translation of proteins and elucidate their mechanism of action in a new target space.\u00a0Our pipeline includes programs in Fibrosis (tissue selective Collagen I translation inhibitors), Oncology (cMyc translation inhibitors), RSV (viral translation inhibitors), Huntington&#8217;s disease (selective inhibition of the mutant mHTT) and our $1B partnership with Lilly around several Neuroscience\u00a0targets. Our science was further validated with seven patents, 15 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VetkYe6PmAznmYiTfL1E68PLhLw0zzMH0tKmH4W8eCvhQ-ZCMbzuuOvbhdtnB-YFAZ3-QsTsCG3hw07R-PaRw9BMdh-pogzo2DOCmlFzNDs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.animabiotech.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Andrew Mielach <br \/>LifeSci Communications<br \/>+1.646.876.5868<br \/>amielach@lifescicomms.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b51546b9-91da-4697-b2ca-cf6e02817e2d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BERNARDSVILLE, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) &#8212; Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced the company will be both presenting and participating in multiple expert sessions during the 3rd Annual RNA-Targeted Drug Discovery Conference, between Dec. 8-10, 2020. During the virtual meeting, Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will be giving a company presentation during the meeting and will also serve on an expert panel. Concurrently, Iris Alroy, Ph.D., Vice President of Research and Development at the company, will serve on an expert Q&amp;A panel. Details regarding each session are as follows: Ev ent Title : Translation Control Therapeutics: Discovery of Selective mRNA Translation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-395582","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERNARDSVILLE, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) &#8212; Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced the company will be both presenting and participating in multiple expert sessions during the 3rd Annual RNA-Targeted Drug Discovery Conference, between Dec. 8-10, 2020. During the virtual meeting, Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will be giving a company presentation during the meeting and will also serve on an expert panel. Concurrently, Iris Alroy, Ph.D., Vice President of Research and Development at the company, will serve on an expert Q&amp;A panel. Details regarding each session are as follows: Ev ent Title : Translation Control Therapeutics: Discovery of Selective mRNA Translation &hellip; Continue reading &quot;Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-08T15:20:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference\",\"datePublished\":\"2020-12-08T15:20:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/\"},\"wordCount\":392,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/\",\"name\":\"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==\",\"datePublished\":\"2020-12-08T15:20:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/","og_locale":"en_US","og_type":"article","og_title":"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference - Market Newsdesk","og_description":"BERNARDSVILLE, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) &#8212; Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced the company will be both presenting and participating in multiple expert sessions during the 3rd Annual RNA-Targeted Drug Discovery Conference, between Dec. 8-10, 2020. During the virtual meeting, Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will be giving a company presentation during the meeting and will also serve on an expert panel. Concurrently, Iris Alroy, Ph.D., Vice President of Research and Development at the company, will serve on an expert Q&amp;A panel. Details regarding each session are as follows: Ev ent Title : Translation Control Therapeutics: Discovery of Selective mRNA Translation &hellip; Continue reading \"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-08T15:20:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference","datePublished":"2020-12-08T15:20:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/"},"wordCount":392,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/","name":"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==","datePublished":"2020-12-08T15:20:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODcwNSMzODYxNjg5IzUwMDA1MjgzMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anima-biotech-to-participate-in-the-3rd-annual-rna-targeted-drug-discovery-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anima Biotech to Participate in the 3rd Annual RNA-Targeted Drug Discovery Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=395582"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395582\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=395582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=395582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=395582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}